February 28, 2022
Researchers led by the University of Cincinnati's Dr. Trisha Wise-Draper led a clinical trial that showed immunotherapy drug pembrolizumab increased survival rates for head and neck cancer patients with intermediate risk.
February 9, 2022
Precision and toughness have been engrained in the University of Cincinnati's Dr. Alicia Heelan from a young age, and her time as a Team USA figure skater has prepared her for her current work as a breast cancer surgeon.
November 3, 2022
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, is co-corresponding author of new research in JAMA Oncology that provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
November 2, 2022
A collaborative research team at the University of Cincinnati has received a $3.5 million National Institutes of Health grant to examine how current HIV medications are affected by alcohol use alone or in combination with fentanyl.
November 15, 2022
The University of Cincinnati's Jeffrey Strawn led research that found in utero exposure to certain flame retardant chemicals may be a risk factor for developing anxiety symptoms in early adolescence.
May 24, 2022
The University of Cincinnati's College of Medicine and College-Conservatory of Music collaborate on the innovative Dementia and the Arts course and intervention for community members with cognitive disorders and their family members.
September 29, 2021
UC experts explain how public health guidelines like mask requirements affects anxiety levels among groups of people, including children, first responders and other front line workers.
May 23, 2022
The University of Cincinnati's Dr. Jennifer O’Toole is co-editor of the book “Women in Pediatrics: The Past, Present and Future.”
July 11, 2022
Over decades of ups and downs, the hard work of University of Cincinnati alumnus John Drach paid off when the FDA approved a new drug he helped develop to treat cytomegalovirus.
August 10, 2022
University of Cincinnati researchers Jason Gardner and Matthew Robson are studying whether targeting an inflammation pathway that affects burns and traumatic brain injuries can be an effective treatment for both conditions.